3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
2
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Acute
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Myeloproliferative Disorders
1
Myeloid Malignancy
1
MDS
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Rituximab
155
Cyclophosphamide
120
fludarabine phosphate
71
Whole-Body Irradiation
55
Mycophenolic Acid
54
Etoposide
53
Peripheral Blood Stem Cell Transplantation
46
fludarabine
45
Melphalan
44
Granulocyte Colony-Stimulating Factor
43
Busulfan
43
Tacrolimus
39
Filgrastim
37
Vincristine
33
Cyclosporine
31
Bendamustine Hydrochloride
31
Prednisone
29
Doxorubicin
29
Antilymphocyte Serum
28
Methotrexate
27
Cytarabine
27
Lenalidomide
23
Carmustine
22
Bortezomib
22
plerixafor
20
Dexamethasone
19
Thiotepa
17
Stem Cell Transplantation
17
Radiotherapy
17
tositumomab I-131
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, Non-Hodgkin
×
eprenetapopt
×
Clear all
NCT04419389
2025-03-17
R/R
Aprea Therapeutics
Phase 1/2
Terminated
1 enrolled
4 charts